骨誘導(dǎo)因子(OGN)重組蛋白
Recombinant Osteoglycin (OGN)
OIF; SLRR3A; Mimecan Proteoglycan; Osteoinductive Factor
- 編號URPC688Mu01
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 來源原核表達
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測定)
- 亞細胞定位分泌
- 預(yù)測分子量14.9kDa
- 實際分子量16kDa(差異分析請參閱說明書)
- 片段與標簽Leu180~Phe298 (Accession # Q62000) with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 97%
- 等電點9.61
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請參見活性蛋白。 - 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 540 ¥ 1350 ¥ 2700 ¥ 8100 ¥ 20250
- 欲了解實際交易價格和更多情況，請與當?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
SDS-PAGE圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認證
序列
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復(fù)凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當?shù)臈l件下存儲，損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPC688Mu02 | 骨誘導(dǎo)因子(OGN)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPC688Mu01 | 骨誘導(dǎo)因子(OGN)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAC688Mu01 | 骨誘導(dǎo)因子(OGN)多克隆抗體 | WB; IHC |
| UPAC688Mu02 | 骨誘導(dǎo)因子(OGN)多克隆抗體 | WB; IHC; ICC; IP. |
| ULAC688Mu71 | 骨誘導(dǎo)因子(OGN)多克隆抗體(生物素標記) | WB |
| USEC688Mu | 骨誘導(dǎo)因子(OGN)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMC688Mu | 骨誘導(dǎo)因子(OGN)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| Bone. | Association of osteoglycin and FAM5C with bone turnover markers, bone mineral density, and vertebral fractures in postmenopausal women with type 2 diabetes mellitus. [pubmed:27836731] |
| Tohoku journal of experimental medicine | Higher Serum Levels of Osteoglycin Are Associated with All-Cause Mortality and Cardiovascular and Cerebrovascular Events in Patients with Advanced Chronic Kidney Disease. [pubmed:28824047] |
| Molecular Metabolism | Osteoglycin, a novel coordinator of bone and glucose homeostasis [Pubmed:29799418] |
| Journal of Experimental &?Clinical?Cancer?Research | Osteoglycin (OGN) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via EGFR/Akt pathway [Pubmed:29499765] |
| Journal of Human Hypertension | Association of SLRPs with carotid artery atherosclerosis in essential hypertensive patients [Pubmed:29867136] |
| Cell?Reports | Transforming Growth Factor-β3 Regulates Adipocyte Number in Subcutaneous White Adipose Tissue [Pubmed: 30332637] |
| J Clin Endocrinol Metab | Osteoglycin across the adult lifespan [34850904] |
留言咨詢
